AQST vs INVA vs PRGO vs DARE

For growth investors, Innoviva, Inc.

(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus -99. 7% for Daré Bioscience, Inc. (DARE). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Aquestive Therapeutics, Inc. (AQST) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 5%, compared to -82. 2% for Daré Bioscience, Inc. (DARE). Over 10 years, the gap is even starker: INVA returned +95. 6% versus DARE's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 11β versus Aquestive Therapeutics, Inc. 's 1. 26β — meaning AQST is approximately 1004% more volatile than INVA relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Innoviva, Inc.

(INVA) is pulling ahead at 18. 5% versus -99. 7% for Daré Bioscience, Inc. (DARE). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, INVA leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 7. 3x for Innoviva, Inc. — 1. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

In this comparison, PRGO (9.

8% yield) pays a dividend. AQST, INVA, DARE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 11)). Both have compounded well over 10 years (INVA: +95. 6%, AQST: -73. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AQST is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; DARE is a small-cap quality compounder stock. PRGO pays a dividend while AQST, INVA, DARE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.